Another Paragon offshoot inks reverse merger as Jade takes Aerovate’s place
Paragon Therapeutics, a company that spins out antibody biotechs, has forged a second reverse merger for its portfolio this week.
Its autoimmune spinoff Jade Biosciences …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
